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Molecular human papillomavirus (HPV) testing
is an important and developing tool for cervical
disease management. However there is a re-
quirement to develop new HPV tests that can
differentiate between clinically significant and
benign, clinically insignificant infection. Evi-
dence would indicate that clinically significant
infection is linked to an abortive HPV replication
cycle. In particular the later stages of the
replication cycle (i.e., production of late mes-
senger (m) RNAs and proteins) appear compro-
mised. Compared to current DNA-based tests
which indicate only presence or absence of
virus, detecting virus mRNAs by reverse tran-
scriptase PCR (RT-PCR) may give a more
refined insight into viral activity and by implica-
tion, clinical relevance. A novel quantitative (q)
RT-PCR assay was developed for the detection
of mRNAs produced late in the viral replication
cycle. Initially this was validated on HPV-con-
taining cell lines before being applied to a
panel of 223 clinical cervical samples represent-
ing the cervical disease spectrum (normal to
high grade). Samples were also tested by a
commercial assay which detects expression of
early HPV E6/E7 oncoprotein mRNAs. Late
mRNAs were found in samples associated with
no, low and high grade disease and did not
risk-stratify HPV infection. The data reveal hid-
den complexities within the virus replication
cycle and associated lesion development. This
suggests that future mRNA tests for cervical
disease may require quantitative detection of
specific novel viral mRNAs. J. Med. Virol.
86:627–633, 2014. # 2013 Wiley Periodicals, Inc.
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INTRODUCTION
Persistent infection with “high risk” human papillo-
mavirus (HR-HPV) genotypes is a necessary cause of
cervical and other anogenital cancers [Walboomers
et al., 1999; Munoz et al., 2003; Woodman et al.,
2007; Bodily and Laimins, 2011]. Cytology-based
cervical screening programs are only protective in
part and lack sensitivity. HPV DNA testing has been
introduced in several counties to improve sensitivity
of cervical disease detection. Most HPV DNA tests
used for cervical disease management are based on
PCR detection of the L1 gene region. Although the
tests are sensitive they cannot separate those infec-
tions that are clinically significant from those which
are clinically irrelevant [Cuzick et al., 2006]. Thus
more sophisticated tests are required to improve the
specificity of HPV testing. Basic research can inform
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the development of such tests. Molecular studies of
the HPV replication cycle have led to a number of
key insights [Doorbar, 2005]. First, increased expres-
sion of HPV E6/E7 oncoproteins underpins cervical
tumorigenesis. Second, productive infections where
progeny virions are synthesized follow a full viral
gene expression program (early and late events) and
are rarely associated with malignancy. Third, persis-
tent infections that can lead to malignancy are those
where normal cell function is abrogated and where
late events in the viral replication cycle are not
supported or are supported only poorly.
Importantly, only active infections are clinically
relevant. Their hallmark is production of viral mes-
senger (m)RNAs and proteins. The low level of virus
protein expression during infection and lack of good
antibodies makes protein detection difficult. However,
viral mRNAs encoding the proteins can be detected
by reverse transcriptase (RT) PCR.
Tests to detect E6/E7 mRNA are available already.
Increased expression of E6/E7 mRNA is hypothesized
to mark clinically significant infections. Indeed, E6/
E7 mRNA tests may show enhanced specificity in
detecting clinically significant disease compared to
DNA tests [Spathis et al., 2012; Cuzick et al., 2013].
However, E6/E7 mRNA detection itself is not entirely
specific for clinically significant infection because E6/
E7 mRNA expression seems to occur in both produc-
tive and persistent infection [Arbyn et al., 2013].
HPV capsid (late) proteins L1 and L2 expressed in
the uppermost layers of the epithelium, are the
ultimate markers of a productive infection, and are
produced at reduced levels in persistent abortive
infections [Middleton et al., 2003]. The capsid pro-
teins are encoded by the viral late mRNAs that all
contain L1 RNA sequences. With particular reference
to HPV16, the hypothesis that late mRNA (L1)
detection would identify productive infections less
likely to be associated with significant underlying
disease was tested.
MATERIALS AND METHODS
Clinical Sample Panel
The clinical panel constituted archived (stored at
80˚C) cervical liquid based cytology (LBC) samples
obtained from 223 women who had attended a
colposcopy (all referral) clinic at the Simpsons Centre
for Reproductive Health, Royal Infirmary of Edin-
burgh. Ethical approval for sample use was provided
by Fife and Forth Valley Research Ethics Committee
(reference number 07/S0501/92). Informed consent
was obtained for sample collection and use. The panel
selected for the study was composed of HPV-positive
samples, representing the disease spectrum ranging
from normal to cervical intraepithelial neoplasia
grade 3. HPV status was confirmed by the Aptima
HPV Assay (AHPV assay, GenProbe, San Diego, CA),
a broad spectrum qualitative HPV E6/E7 mRNA test
that detects 14 high risk (or putatively high risk)
types in aggregate. All experiments were performed
in compliance with relevant laws and institutional
guidelines and in accordance with the ethical stand-
ards of the Declaration of Helsinki.
Growth of Cell Lines
W12E (clone 20863). Immortal cell line derived
from a low grade cervical lesion [Stanley et al., 1989;
Jeon et al., 1995] containing episomal HPV16 ge-
nomes. Epithelial cells were co-cultured in E-medium
with mitomycin C-treated J2 3T3 fibroblast feeder
cells at a ratio of 1:5, seeding keratinocytes at 2 105
cells/100mm dish [Jeon et al., 1995]. Cells were
cultured for 10 days with 1.2mM Ca2þ to allow
epithelial differentiation and production of virus
capsid proteins [Milligan et al., 2007].
W12G cells (clone 20861). Immortal cell line
derived from W12E containing mostly integrated
HPV16 genomes [Jeon et al., 1995]. W12G cells were
cultured exactly as W12E cells.
W12GPXY cells. Transformed invasive cell line
containing integrated HPV16 genomes derived from
W12G cells [Aasen et al., 2003].
HaCaT cells. Immortalized keratinocytes with-
out HPV DNA [Boukamp et al., 1988].
HaCaT and W12GPXY cells were grown in DMEM,
10% foetal bovine serum, 2mM glutamine without
feeder cells.
RNA Extraction and RT-PCR Detection
of HPV mRNAs
Prior to RNA extraction fibroblast feeder cells were
removed from W12E and W12G cells by trypsiniza-
tion. RNA from all cells was prepared using Trizol
(Life Technologies, Carlsbad, CA) according to the
manufacturer’s protocol and DNA was removed by
TURBODNase (Life Technologies) treatment accord-
ing to the manufacturer’s protocol. SuperScript III
First-Strand Synthesis System for RT-PCR (Life
Technologies) was used for cDNA synthesis. RT-
negative controls contained RNA and all reagents
except reverse transcriptase. Semi-quantitative PCR
was used to simultaneously amplify cellular GAPDH and
HPV L1 cDNA. Primers used are shown in Table Ia.
Products were resolved on 6% acrylamide gels and
visualized by staining with ethidium bromide.
DNA Genotyping
Automated DNA extraction was performed on LBC
samples using a Qiagen MDX machine in conjunction
with the QIAamp Media MDX Kit (Qiagen, Man-
chester, UK). In order to characterize which samples
harbored HPV16, PCR and genotyping of amplicons
was performed using a luminex-based assay (Multme-
trix HPV Genotyping Kit from Progen, Heidelberg,
Germany) which can delineate the presence of 24 low
and high risk HPVs including type 16 [Schmitt et al.,
2006].
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Development of a qRT-PCR Assay for HPV L1
MIQE pre´cis guidelines were followed for design
and implementation of the qRT-PCR assay [Bustin
et al., 2010].
RNA extraction—clinical samples. Cells from
4ml LBC cell suspensions in PreservCyt collection
medium (Cytyc Corporation, Marlborough, MA) were
pelleted by centrifugation in a Beckman GPR bench
top centrifuge at 1,500g for 10min. The supernatant
was decanted and the cell pellet washed with sterile
PBS pre-treated with 0.1% v/v DEPC (Sigma, Poole,
UK). RNA extraction was optimized on aliquots of
the clinical samples. Three RNA extraction kits:
RNeasy (Qiagen) and RNeasy FFPE (Qiagen) and
MasterPure (Life Technologies), were evaluated. RNA
was quantified and purity assessed by measuring
the ratio of absorbance at 260 and 280nm using a
Nanodrop ND-1000 spectrophotometer. Integrity of
selected RNAs was assessed using an Agilent 2100
Bioanalyser. MasterPure gave best yields and purity
of RNA.
cDNA synthesis. cDNA synthesis was performed
on DNase-treated extracted nucleic acid using a
Stratagene AffinityScript qPCR cDNA synthesis
kit (Agilent Technologies, Santa Clara, CA) in accor-
dance with the manufacturer’s instructions. RT-nega-
tive controls containing RNA and all reagents except
reverse transcriptase were prepared for all samples.
Primer/probe selection. The specificity of eight
different probe/primer sets within the L1 gene region
was validated in silico (BLAST). Optimal annealing
temperature was assessed by gradient PCR and
primer and Mg2þ concentrations were also optimized
using cDNA prepared from RNA isolated from W12E
cells (active HPV16 infection). The primers were
evaluated in qRT-PCR using serial dilutions of W12E
cell RNA. The optimal probe-primer set was L1-1
(Table Ib) with a threshold cycle (Ct) value compati-
ble with the control b-actin and GAPDH probe/primer
sets (98% efficiency). For analysis of the LBC samples
qRT-PCR primers and FAM/TAMRA dual labeled
probes were supplied by Eurogentec (Southhampton,
UK). qRT-PCR Mastermix was Stratagene Brilliant
qPCR Mastermix (Agilent Technologies), reference
dye was ROX supplied with the Mastermix. For each
primer/probe set the reaction contained 1 Master-
mix, 900nM forward primer, 900nM reverse primer
100nM probe, 300nM ROX in a final volume of 23ml.
Reactions were carried out in Thermofast 96ml 0.2
ml well non-skirted PCR plates (Thermo Fisher,
Loughborough, UK). Addition of 2ml template to each
well was used to start the reactions. Quantity of
template was 0 (non-template control) or 10ng cDNA
or 10ng cDNA reaction without reverse transcriptase
added to test for presence of residual DNA. All
samples were assayed in triplicate. A calibrator
consisting of 10ng of cDNA prepared from RNA
extracted from 3.14 103 W12E cells mixed with
2.6 106 HaCaT cells was used on every plate. qRT-
PCR results were plotted as Ct value versus log
dilution factor. qRT-PCR was carried out on an
Applied Biosystems (Life Technologies, Carlsbad, CA)
7500 real time PCR machine with the following
thermocycling conditions: 50˚C for 2min; 95˚C for
10min; then 40 cycles of 95˚C for 15 sec, 60˚C for
1min; well volume 25ml. Applied Biosystems soft-
ware was used for data analysis.
E6/E7 mRNA Type Specific Testing
Samples that were shown to harbor HPV16 infec-
tion were also tested with the PreTect HPV Proofer
(Norchip A, Klokkarstua, Norway). This is a NASBA-
based assay which incorporates the qualitative detec-
tion of full-length E6/E7 mRNA for 5 HR-HPV types
using molecular beacons (16, 18, 31, 33, and 45).
RESULTS
Evaluation of LBC mRNA and q-RT-PCR for
Late mRNA Detection
Eight Taqman primer and probe sets covering
different regions of the L1 ORF were designed and
evaluated using cDNA prepared from W12E cells,
which are cervical intraepithelial neoplasia grade 1-
derived cells with the HPV16 genome in the episomal
form. Standard curves were plotted and efficiencies
for all of these sets were calculated and compared to
those for concurrent standard curves prepared from
existing primer and probe sets for b-actin and
GAPDH, two housekeeping genes. Three of the L1
primer/probe sets were found to have compatible
efficiency with the control primer/probe sets and of
these, the one with the lowest Ct value at the log
relative dilution factor of 0 (neat sample) was chosen
as the set to use to assay the LBC samples. The
amplicon (Table Ib) was located in the last third of
the L1 open reading frame which is present in all
late mRNAs. Since the L1 and b-actin and GAPDH
TABLE IA. Primer Sequences for RT-PCR
Primer name HPV genome position (nt) Sequence 50–30
16L1-F 7003–7024 CTGCAGACCTAGATCAGTTTCC
16L1-R 7312–7289 GCATGACACAATAGTTACACAAGC
GAPDH-F N/A AGGAAATGAGCTTGACAAAG
GAPDH-R N/A ACCACAGTCCATGCCATCAC
F, forward primer; R, reverse primer.
J. Med. Virol. DOI 10.1002/jmv
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primer/probe sets had comparable efficiencies, the
ddCt method of relative quantification was employed.
Detection of HPV16 late mRNA using the primer
set in Table Ia was tested in W12 cells as an in vitro
model of HPV16 infection and in a small preliminary
clinical panel of 8 LBC samples. Late (L1) mRNA
was detected by semi-quantitative RT-PCR in W12E
cells (Fig. 1A, track 2). These cells were established
from a low grade cervical lesion, contain 100
HPV16 episomal genomes and are capable of support-
ing the complete viral replication cycle [Stanley
et al., 1989]. W12G and W12GPXY cells are models
of persistent, abortive HPV infection. Only a faint
band representing late mRNA was detected in W12G
cells (Fig. 1A, track 4), where most HPV16 genomes
are integrated into the host genome [Jeon et al.,
1995] and no late mRNA was detected in W12GPXY
cells (Fig. 1A, track 6) that contain only integrated
HPV genomes and are fully transformed and invasive
[Aasen et al., 2003]. GAPDH was used as an internal
loading control in this assay. Late mRNAs were also
detected in three (LBC-A, B, and C) out of eight
HPV16-positive archived LBC samples. A representa-
tive RT-PCR analysis is shown in Figure 1B. GAPDH
control was not detected in this experiment.
RNA Quality in LBC Samples
Overall, RNA quality from the archived LBC
samples was extremely variable. Figure 2 shows a
comparison of bioanalyzer profiles of freshly prepared
W12E RNA (Fig. 2A) and RNA prepared from two
archived LBC samples (Fig. 2B,C). Ribosomal RNA
peaks were predominant in the W12E RNA sample
but absent in one of the clinical samples (LBC1) and
partially degraded in the other (LBC2). Despite this,
qRT-PCR was possible for all LBC samples with both
the control b-actin and GAPDH probe/primer sets.
Table II shows the average value and range of values
for detection of the controls in qRT-PCR of cDNAs
synthesized from W12E cell RNA and from LBC
RNAs. The average Ct values were greater for LBC
samples as was the range of values as expected due
to the variable quality of these RNAs.
Characterization of the Clinical Panel
HPV DNA typing using the luminex assay indicat-
ed HPV16-positivity in 98/223 archived LBC samples:
43 appearances with another type (or types) and as a
mono-infection in 55 samples. As the late mRNA
assay was designed to be specific for HPV16, further
analysis was confined to the 98 HPV16-positive
samples. Complete clinical data was available for 88
of the 98 samples: 45 were associated with no
significant disease and comprised normal histology,
normal colposcopy/inflammation only (no biopsy indi-
cated) or cervical intraepithelial neoplasia grade 1. A
TABLE IB. Primer and Probe Sequences for qRT-PCR
Primer name HPV genome position (nt) Sequence 50–30
16L1-1-F 6576–6593 CAACGAGCACAGGGCCAC
16L1-1-R 6661–6688 GAAGTAGATATGGCAGCAC
16L1-1 Probe 6615–6650 CCAACTATTTGTTACTGTTGTTGATACTACACGCAG
Actin-F N/A GGGATGTTTGCTCCAACCAA
Actin-R N/A GCGCTTTTGACTCAAGGATTTAA
Actin probe N/A CGGTCGCCTTCACCGTTCCAGTT
GAPDH-F N/A GAAGGTGAAGGTCGGAGT
GAPDH-R N/A GAAGATGGTGATGGGATTTC
GAPDH probe N/A CAAGCTTCCCGTTCTCAGCC
F, forward primer; R, reverse primer. Probes were FAM/TAMRA labeled.
Fig. 1. HPV16 late mRNA can be detected in cervical cell
lines that support the complete viral replication cycle and
in mRNA prepared from archived LBC samples. A: RT-PCR
amplification (35 cycles) of HPV16 late mRNA from W12E
(episomal HPV16 genome), W12G (mainly integrated HPV16
genomes) and W12GPXY (fully integrated HPV16 genomes)
cells using primer set 16L1-F/R (Table Ia). Detection of GAPDH
cDNA was used as an internal control. B: RT-PCR amplification
(35 cycles) of HPV16 late mRNA from three LBC samples. LBC
samples are labeled A, B, and C to distinguish them from those
used in Figure 2 (LBCs 1 and 2). M, marker track. ()
Amplification in the absence of reverse transcriptase. (þ)
Amplification in the presence of reverse transcriptase.
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total of 43 cases were associated with histologically
confirmed high-grade disease (cervical intraepithelial
neoplasia grade 2þ).
Relation of Late mRNA Positivity to Clinical
Outcomes and E6/E7 mRNA Detection
HPV16 late mRNA qRT-PCR was performed
blinded to the underlying pathology. Of the 98
HPV16 DNA positive samples, 82 were negative for
the L1 qRT-PCR and 16 were positive. Of the
positives, 9/16 (56.2%) were associated with high-
grade disease and 7/16 (43.7%) were associated with
no or low grade disease (Table III). In the case of
multiple HPV infections it is challenging to attribute
the HPV type responsible for any abnormality, we
therefore stratified qRT-PCR status according to
disease and mono- or multiple-infection (associated
with HPV16). A total 9 of the 16 L1 qRT-PCR
positive samples were associated with HPV16 mono-
infection, of which 6 were associated with high grade
disease and 3 were associated with no disease
(Table III). Therefore L1 mRNA detection did not, in
itself risk-stratify HPV infections according to cross
sectional disease status.
Due to the variable quality of the RNA extracted
from the archived LBC samples only 44 of the 98
HPV16 positive samples were evaluable by the E6/E7
Proofer assay (as evidence by lack of amplification of
the internal control). The lack of detection of E6/E7
in all of the samples likely reflects the suboptimal
quality of RNA in archived LBC samples and the fact
that the U1A housekeeping amplicon is a low abun-
dance housekeeping gene [Molden et al., 2007]. Of
this subset 36 had available disease outcomes incor-
porating a total of 16 cervical intraepithelial neopla-
sia grade 2þ The proofer assay tested positive in 10
of these 16 cases (62.5%) and 12 of the 20 cases
where no or low grade disease was detected (60%).
Only 4/44 of the samples that were evaluable by
proofer tested positive for the L1 qRT-PCR; none of
which were associated with high-grade disease. Of
the 4 L1 qRT-PCR positives, 3 were also positive by
the proofer.
DISCUSSION
The presence of HPV late proteins in the upper
layers of infected epithelia has been proposed as a
negative prognostic marker of disease severity [Mid-
dleton et al., 2003]. Early in situ hybridization
studies showed HR-HPV late RNAs were present in
cells of the upper epithelial layers in low grade
cervical lesions [Crum et al., 1988; Beyer-Finkler
et al., 1990; Stoler et al., 1992] and absent in high
grade lesions [Stoler et al., 1992]. Late events in the
HPV replication cycle, including late mRNA produc-
tion, are tightly linked to terminal epithelial differen-
tiation, so reduced differentiation capacity—a
hallmark of high grade lesions—could lead to abor-
tive infection and diminished late mRNA expression
[Middleton et al., 2003]. Viral late mRNA was able to
be detected by a technically validated L1 qRT-PCR in
LBC samples representing different grades of disease
Fig. 2. Quality of RNA isolated from archival LBC samples.
RNA was analyzed on an Agilent 2100 bioanalyzer. A: RNA
isolated from differentiated W12E cells. Peaks at 18S and 28S
corresponding to rRNAs are indicated (asterisks). B: Poor
quality RNA isolated from an LBC sample. C: RNA from a
different LBC sample showed a wider range of sizes with a
detectable 18S ribosomal RNA peak (asterisk).
TABLE II. Average and Range Ct Values for the Control b-Actin and GAPDH Amplifications in W12 Cells and in LBC
Samples
Sample type
GAPDH b-Actin
Average Ct value Range of Ct values Average Ct value Range of Ct values
W12E cells 20.52 19.20–22.12 20.10 19.43–21.78
LBC samples 23.48 19.54–28.32 22.95 19.16–27.16
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but the data show that detection of late mRNA did
not risk-stratify samples into a “lower” risk group
according to underling disease status. There are
caveats to the study/interpretation. First, archived
samples were used where the quality of recoverable
RNA is highly variable and significantly less than
that of freshly collected samples [Cuschieri et al.,
2005]. Further validation using freshly collected LBC
samples would be beneficial. Second, multiple infec-
tions confound type specific-attribution for underlying
pathology. However, when analysis was restricted to
samples associated with a mono-infection of HPV16,
surprisingly, L1 mRNA detection was proportionally
more abundant in samples associated with high
grade disease compared to low-grade, or no disease.
Third the clinical correlations were entirely cross-
sectional; it is feasible that longitudinal assessment
could have revealed differential outcomes associated
with gene expression.
In this study, the performance of the L1 mRNA
PCR was not assessed using standard clinical per-
formance measures of sensitivity, specificity PPV
and NPV. While such measures (and the studies of
prospective populations from which they are derived)
are essential for biomarker validation it is also
essential they are informed, a priori, with pilot,
proof-of-principle studies that demonstrate a correla-
tion between the biomarker under investigation and
disease. This study constituted such a pilot and
provided valuable insight into the limitations of L1
mRNA PCR.
E6/E7 oncogene mRNA expression is expected to
increase with lesion severity while expression of viral
late mRNAs should be greatest in an infectious
situation, that is, low grade disease [Issacson-Wechs-
ler et al., 2012]. This study indicates that the pattern
of clinically significant viral gene expression is more
complex than this and that E6/E7 mRNA and L1
mRNA can be detected both in infections associated
with no disease and in high grade disease, limiting
the ability of these approaches for comprehensive
risk-stratification in their current form [Schmitt
et al., 2011; Arbyn et al., 2013]. The data highlight
lack of detailed knowledge of HPV gene expression in
the cervical epithelium during disease progression
and prior to cancer formation. In addition, lesion
pathology may be complex [Quint et al., 2012] with
multiple simultaneous HPV infections, various viral
loads and different grades of disease within a single
cervical epithelium. Viral gene expression is also
altered depending on the episomal (the infectious
form of the virus genome) or integrated (found more
frequently in high grade lesions) status of the viral
genome and each cervical lesion may exhibit mosai-
cism in this respect. On top of this, epigenetic events
impacting the host or viral genomes may also im-
pinge on viral gene expression at the single cell level,
creating an additional level of complexity [Szalma´s
and Konya, 2009]. The relative stabilities of key viral
mRNAs such as E6/E7 and late mRNAs may also
change during cervical disease progression and con-
found detection strategies [Graham, 2010]. The low
prevalence of late mRNAs supports evidence from
several studies on a number of animal and human
papillomaviruses that showed late mRNAs are unsta-
ble due to the activity of an mRNA decay element in
the late 30 untranslated region [Graham, 2008] and
recent deep sequencing data demonstrating very low
levels of late mRNAs in cell models of HPV16-positive
low grade cervical lesions [Klymenko and Graham,
manuscript in preparation].
CONCLUSIONS
A late mRNA assay for detection of HPV16 infec-
tion applicable to liquid based cytology samples was
developed. Although the assay did not differentiate
clinically insignificant infection, this is the first
molecular study to interrogate its potential in a well
characterized context where HPV status and clinical
data were available. Selective primer/probe sets that
can distinguish individual viral mRNAs and quantify
expression of these compared to bulk viral mRNA
expression may prove more useful as biomarkers of
disease [Schmitt et al., 2010]. It is clear that in
future it would be valuable to interrogate the amplifi-
cation of viral oncogene mRNAs and late mRNAs in
more contemporary or freshly acquired prospective
LBC samples.
TABLE III. Late mRNA Expression in 98 HPV16 Positive Samples and Association With Clinical Outcomes
Grade
Number of
cases overall
Late mRNA
positive overall
Number of
cases associated with
mono HPV16 infection
Late mRNA
positive
Normal 36 7 19 3
CIN1 9 0 3 0
CIN2 20 6 10 3
CIN3 21 3 16 3
High grade undefined 2 1 0
Incomplete record/lost to follow-up 10 6
Total 98 16 55 9
All samples were collected from referral colposcopy clinics where biopsies were taken as routinely indicated. All samples had previously
tested positive using a broad spectrum E6/E7 mRNA test.
J. Med. Virol. DOI 10.1002/jmv
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